[Does early high dosage dipyridamole in prevention of secondary stroke induce cardiac events?].
In a post hoc analysis of the European Stroke Prevention Study 2 (ESPS2), we investigated whether dipyridamole given as antiplatelet drug in patients with TIA or stroke increases the risk of cardiac events. ESPS2 was a secondary prevention trial including 6602 patients with TIA or stroke. Patients were randomized into one of four treatment arms: 2 x 25 mg acetylsalicylic acid (ASA), 2 x 200 mg slow release dipyridamole (DP), the combination of DP and ASA and placebo. DP did not result in a higher number of cardiac events, e.g., angina pectoris, myocardial infarction or death. The combination of ASA plus DP was superior to either drug alone in the prevention of strokes.
Diener
H C
HC
Klinik und Poliklinik für Neurologie der Universität Essen Hufelandstr. 55 45122 Essen, Germany. h.diener@uni-essen.de
Darius
H
H
Bertrand-Hardy
J M
JM
Humphreys
M
M
D000284:Administration, Oral; D000787:Angina Pectoris / Q000139:chemically induced* / Q000401:mortality; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects; D002423:Cause of Death; D002544:Cerebral Infarction / Q000188:drug therapy* / Q000401:mortality; D003692:Delayed-Action Preparations; D004176:Dipyridamole / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006801:Humans; D002546:Ischemic Attack, Transient / Q000188:drug therapy* / Q000401:mortality; D009203:Myocardial Infarction / Q000139:chemically induced* / Q000401:mortality; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D012008:Recurrence; D012307:Risk Factors
D003692:Delayed-Action Preparations; D010975:Platelet Aggregation Inhibitors; D004176:Dipyridamole; D001241:Aspirin